Cartalax is the tripeptide Ala-Glu-Asp from Vladimir Khavinson's St. Petersburg group. Its developers report finding AED at 0.02% of a polypeptide complex extracted from animal cartilage.
Cartalax Prices
22 vendors · 1 with an issuer-verified COA · lowest 10mg from $33.60 · checked
Where to buy Cartalax: 22 vendors compared
Tracked every day
Cartalax listing prices, tracked daily
The five cheapest in-stock package prices for Cartalax on each collected day, and the vendors that most often held those places.
No collected listings for this compound yet.
Current market data
Cartalax Price Report
A current summary of public listings after the price comparison above. Shipping and tax are not included.
The lowest current 10mg cost for Cartalax is $33.60 from Real Peptides. The median across vendors is $51.49.
- Lowest 10mg cost
- $33.60Real Peptides
- Median 10mg cost
- $51.49One normalized offer per vendor
- Lowest package total
- $33.60Real Peptides · package size may differ
- Public COA coverage
- 95%21 of 22 vendors
What the market shows
PeptidePrices found 22 in-stock listings from 22 vendors, checked through Oct 8, 2026. The lowest 10mg cost is 35% below the vendor median of $51.49; 11 vendors (50%) fall below that median. 21 of 22 vendors (95%) publish public COA evidence.
A public COA link shows that a vendor publishes testing data. It does not prove that every listed vial has a matching current report. Match the product, strength, batch, and lot before relying on a report.
How this report is calculated
The headline and median use each vendor's lowest whole-package checkout cost to obtain at least 10mg. Smaller packages are multiplied until the target is met, while larger packages retain their full checkout price. The lowest package total is shown only as secondary context because package sizes differ. Known public coupon discounts are applied. Shipping, tax, and unverified promotions are excluded.
Research context
What is Cartalax? Research, safety, and status
Cartalax is three amino acids: alanine, glutamic acid, aspartic acid. In the Khavinson papers it also shows up as T-31. It is one of a family of two-to-four-residue peptides the group calls bioregulators, and it overlaps with them in sequence. Epitalon is Ala-Glu-Asp-Gly and Cortagen is Ala-Glu-Asp-Pro. Cartalax is the shared Ala-Glu-Asp core with nothing added.
The group's proposed mechanism is the same for the whole family. The short peptide enters the cell nucleus, binds DNA or histones at particular sequences, and nudges gene expression back toward a younger pattern. For AED, a 2014 paper built computer models of the peptide sitting in the DNA minor groove at AT-rich sequences and concluded that this binding was "the cause" of the gene changes it saw in kidney cells. Those were models fitted after the experiments. The developers' own 2021 systematic review says "there are very few studies in this area".
Key research takeaways
Every indexed study we found is cell culture: stem cells, skin fibroblasts, kidney cells, thymocytes. We found no peer-reviewed animal study of AED in a joint or cartilage injury model.
A 2023 review by the developers says AED worked in animal models of osteoarthritis and in older patients taking it by mouth. We could not find the primary papers behind either claim.
Vendor pages disagree on what Cartalax even is. One calls it a dipeptide (Ala-Glu, about 218 Da). If a vendor's sequence or mass does not match 333 Da, that is a labeling problem, not a variant.
Not known: absorption by any route, half-life, whether it reaches cartilage, and any result from a lab with no tie to the developers.
Cartalax at a glance
PeptidePrices safety rating
6/10 · Not FDA-approved
Mechanism
Proposed short-peptide bioregulator that may influence gene expression in cartilage, skin and kidney cells. Effects are reported in cell-culture and animal studies.
Research areas
Cartilage and joint-tissue bioregulator research. Human clinical benefit is not established.
Regulatory / research status
Research / preclinical only
Half-life
Not established in direct human pharmacokinetic studies.
Storage
Lyophilized vial: store at -20°C long-term or 2-8°C short-term, protected from light.
Reported side effects
Human safety data is sparse. The available evidence is mainly preclinical and small Russian studies from one research group, and it does not establish clinical efficacy.
Russian bioregulator; short peptide; limited but clean data. Human evidence is thin and mostly from one research group. Safety ratings summarize published clinical data, adverse-event reporting, and regulatory status. How PeptidePrices rates evidence. Research information only, not medical advice.
Study highlights
- Cartalax is the tripeptide Ala-Glu-Asp from Vladimir Khavinson's St. Petersburg group. Its developers report finding AED at 0.02% of a polypeptide complex extracted from animal cartilage.
- Every indexed study we found is cell culture: stem cells, skin fibroblasts, kidney cells, thymocytes. We found no peer-reviewed animal study of AED in a joint or cartilage injury model.
- A 2023 review by the developers says AED worked in animal models of osteoarthritis and in older patients taking it by mouth. We could not find the primary papers behind either claim.
- Vendor pages disagree on what Cartalax even is. One calls it a dipeptide (Ala-Glu, about 218 Da). If a vendor's sequence or mass does not match 333 Da, that is a labeling problem, not a variant.
Selected references
- [Identification of short peptides in polypeptide complexes isolated from animal organs] · khavinson.info, 2020
- Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides · PubMed, 2020
- Peptide regulation of gene expression: a systematic review · PubMed, 2021
- [Chondrocytes secretory phenotype associated with aging: role in the pathogenesis of osteoarthritis and prospects for peptide bioregulation] · PubMed, 2023
- RLS Encyclopedia (rlsnet.ru) · rlsnet.ru
- ClinicalTrials.gov search for "cartalax" and "Ala-Glu-Asp," no matching trials · clinicaltrials.gov
Related pages